{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:50:35Z","timestamp":1792176635269,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02462-4","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:05:18Z","timestamp":1785924318000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of semaglutide introduction on the use of triptans: an interrupted-time series"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-4263","authenticated-orcid":false,"given":"No\u00e9mie","family":"Roland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Sonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfranco","family":"Pellesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Bramming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Gehrt","family":"Card\u00e9l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Kildegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"2462_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s10194-024-01821-3","volume":"25","author":"W Halloum","year":"2024","unstructured":"Halloum W, Dughem YA, Beier D, Pellesi L (2024) Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. J Headache Pain 25:112. https:\/\/doi.org\/10.1186\/s10194-024-01821-3","journal-title":"J Headache Pain"},{"key":"2462_CR2","doi-asserted-by":"publisher","first-page":"137397","DOI":"10.1016\/j.neulet.2023.137397","volume":"812","author":"F Jing","year":"2023","unstructured":"Jing F, Zou Q, Pu Y (2023) GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model. Neurosci Lett 812:137397. https:\/\/doi.org\/10.1016\/j.neulet.2023.137397","journal-title":"Neurosci Lett"},{"key":"2462_CR3","doi-asserted-by":"publisher","unstructured":"Braca S, Russo CV, Stornaiuolo A, et al (2025) Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study. Headache 65:1831\u20131838. https:\/\/doi.org\/10.1111\/head.14991","DOI":"10.1111\/head.14991"},{"key":"2462_CR4","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 389:2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"2462_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM et al (2024) Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 404:773\u2013786. https:\/\/doi.org\/10.1016\/S0140-6736(24)01498-3","journal-title":"Lancet"},{"key":"2462_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1129-2377-14-1","volume":"14","author":"TJ Steiner","year":"2013","unstructured":"Steiner TJ, Stovner LJ, Birbeck GL (2013) Migraine: the seventh disabler. J Headache Pain 14:1. https:\/\/doi.org\/10.1186\/1129-2377-14-1","journal-title":"J Headache Pain"},{"key":"2462_CR7","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/ije\/dyw213","volume":"46","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Schmidt SAJ, Wallach-Kildemoes H et al (2017) Data resource profile: the Danish National Prescription Registry. Int J Epidemiol 46: 798\u2013798f. https:\/\/doi.org\/10.1093\/ije\/dyw213","journal-title":"Int J Epidemiol"},{"key":"2462_CR8","unstructured":"Norwegian Institute of Public Health. ATC\/DDD \u2013 Guidelines (2020). Accessed 29 Apr 2025 https:\/\/atcddd.fhi.no\/atc_ddd_index_and_guidelines\/guidelines\/"},{"key":"2462_CR9","unstructured":"European Medicines Agency (EMA). Wegovy (2022). Accessed 29 June 2026 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/wegovy"},{"key":"2462_CR10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ije\/dyw098","volume":"46","author":"JL Bernal","year":"2017","unstructured":"Bernal JL, Cummins S, Gasparrini A (2017) Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol 46:348\u2013355. https:\/\/doi.org\/10.1093\/ije\/dyw098","journal-title":"Int J Epidemiol"},{"key":"2462_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/JMDH.S241085","volume":"13","author":"JE Ewusie","year":"2020","unstructured":"Ewusie JE, Soobiah C, Blondal E et al (2020) Methods, Applications and Challenges in the Analysis of Interrupted Time Series Data: A Scoping Review. J Multidiscip Healthc 13:411\u2013423. https:\/\/doi.org\/10.2147\/JMDH.S241085","journal-title":"J Multidiscip Healthc"},{"key":"2462_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jeconom.2020.12.001","volume":"225","author":"B Callaway","year":"2021","unstructured":"Callaway B, Sant\u2019Anna PHC (2021) Difference-in-Differences with multiple time periods. J Econ 225:200\u2013230. https:\/\/doi.org\/10.1016\/j.jeconom.2020.12.001","journal-title":"J Econ"},{"key":"2462_CR13","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1192\/j.eurpsy.2024.1803","volume":"68","author":"W Lu","year":"2025","unstructured":"Lu W, Wang S, Tang H et al (2025) Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database. Eur Psychiatry 68:e20. https:\/\/doi.org\/10.1192\/j.eurpsy.2024.1803","journal-title":"Eur Psychiatry"},{"key":"2462_CR14","doi-asserted-by":"publisher","first-page":"A24","DOI":"10.1210\/jendso\/bvab048.046","volume":"5","author":"RF Kushner","year":"2021","unstructured":"Kushner RF, Garvey WT, Hesse D et al (2021) Once-weekly Subcutaneous Semaglutide 2.4\u00a0mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1). J Endocr Soc 5:A24. https:\/\/doi.org\/10.1210\/jendso\/bvab048.046","journal-title":"J Endocr Soc"},{"key":"2462_CR15","doi-asserted-by":"publisher","first-page":"bqae165","DOI":"10.1210\/endocr\/bqae165","volume":"166","author":"S B\u00f6rchers","year":"2025","unstructured":"B\u00f6rchers S, Skibicka KP (2025) GLP-1 and Its Analogs. Does Sex Matter? Endocrinol 166:bqae165. https:\/\/doi.org\/10.1210\/endocr\/bqae165","journal-title":"Does Sex Matter? Endocrinol"},{"key":"2462_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-025-02262-2","volume":"27","author":"A Mohammad","year":"2026","unstructured":"Mohammad A, Iversen DB, Rausgaard NLK et al (2026) Sildenafil provokes headache but not migraine in men with migraine without aura: a randomized, placebo-controlled crossover trial. J Headache Pain 27:16. https:\/\/doi.org\/10.1186\/s10194-025-02262-2","journal-title":"J Headache Pain"},{"key":"2462_CR17","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1212\/01.wnl.0000262045.11646.b1","volume":"68","author":"ME Bigal","year":"2007","unstructured":"Bigal ME, Lipton RB, Holland PR, Goadsby PJ (2007) Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 68:1851\u20131861. https:\/\/doi.org\/10.1212\/01.wnl.0000262045.11646.b1","journal-title":"Neurology"},{"key":"2462_CR18","unstructured":"Schytz H, Bendtsen L (2025) Migr\u00e6ne \u2013 behandling. nNBV (neurologiske Nationale Behandlingsvejledning), Dansk Neurologisk Selskab. Accessed 1 July 2026. https:\/\/nnbv.dk\/migraene-behandling\/"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02462-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02462-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02462-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:12:24Z","timestamp":1785931944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02462-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2462"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02462-4","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to Danish law, studies based solely on register data do not require approval from an ethics review board. All authors have given their consent for publication.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anton Potteg\u00e5rd reports participation in regulator-mandated phase IV-studies funded by AbbVie, Alcon, Almirall, Astellas, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, LEO Pharma, Novo Nordisk, Pfizer, and Servier, and on sponsor-initiated research projects with Novo Nordisk, all with funds paid to the institution where he is employed (no personal fees).\u202fMaja Bramming and Lise Gehrt Card\u00e9l are employees of Novo Nordisk. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"199"}}